Krish Skandha Gopalan

Krish Skandha Gopalan

Auto-generated profile, based on publicly available information

Krish Skandha Gopalan

Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2025 in Science Advances
Verified
Journal Article
Open access
SGSophie Guelfi
Sophie Guelfi
KGKrish Skandha Gopalan
Krish Skandha Gopalan
PMPieter Maene
Pieter Maene
DRDorothy John Robbert
Dorothy John Robbert
CPCarla Pallarés-Moratalla
Carla Pallarés-Moratalla
GBGabriele Bergers
Gabriele Bergers
Blood vascular organoids (BVOs) have emerged as powerful tools for interrogating endothelial heterogeneity, function, and organ-specific cues during development, homeostasis, and disease. Here, we describe the stepwise generation and characterization of murine BVOs from different embryonic stem cells and introduce a fluorescent tracer system to follow their formation and maturation, visualizing functional and perfused vessels after transplantations into mice. Single-cell RNA sequencing, FACS, and whole-mount immunohistochemistry revealed a heterogeneous and dynamic trajectory of multiple endothelial, mesenchymal, and macrophage clusters in mBVOs at growth spike and full maturation. Endothelial cells inferred high plasticity toward arterial, venous, capillary, and tip/stalk cells and a neural-like identity at full maturation state. mBVOs responded to inflammatory cues and VEGF blockade in vitro and could be assembled with tumor spheroids in which tumor cells mimicked the same vascular growth pattern as observed in vivo. Our results highlight mBVOs as adaptable in vitro platforms, unlocking various applications and avenues for discovery in vascular biology.

6 September 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KGKrish Skandha Gopalan
Krish Skandha Gopalan
GBGabriele Bergers
Gabriele Bergers
In the first pan-cancer analysis of the tumor vasculature, Pan and colleagues profile nearly 200,000 endothelial cells (EC) and mural cells, identifying novel subclusters and cell states using consensus trajectory inference. They identify differentiation trajectories in vascular and lymphatic ECs and subtype the pericyte (PC) population. During sprouting angiogenesis, venous cells dedifferentiate and transition to capillary and, finally, arterial ECs. Capillary ECs transition via “three angiogenic stages” (SI–SIII), during which APLN+ TipS1 cells were identified as potential modulators of tumor-induced neovascularization and antiangiogenic therapy response. In lymphatic ECs, differentiation was inversely correlated between the lymphangiogenic (T1) and antigen-presenting (T2) trajectories, with T2 associated with a better prognosis. Although several PC clusters were identified, BASP1+ matrix–associated PCs were associated with APLN+ TipS1 cells and had a worse prognosis. These findings present transcriptional validation of previous experimental findings and serve as a resource to examine the tumor vascular microenvironment in detail.

19 October 2025 in bioRxiv
Verified
Preprint
Open access
LWLinqian Weng
Linqian Weng
KGKrish Skandha Gopalan
Krish Skandha Gopalan
MGMélanie Guyot
Mélanie Guyot
Maxime VanmechelenMaxime Vanmechelen
Maxime Vanmechelen
PNPouya Nazari
Pouya Nazari
GBGabriele Bergers
Gabriele Bergers
Background: Immunotherapies have improved outcomes in many cancers but show limited efficacy in glioblastoma (GBM). This study aimed to determine whether immunotherapy could be tailored to GBM by functional subtyping of vascular-immune landscapes. Methods: We employed single-cell RNA sequencing, multiplex immunohistochemistry to characterize three distinct TIME subtypes in human and murine GBMs. We evaluated responses to combination of anti-angiogenic immunomodulating therapies (CD40 Ag, anti-PDL1, PI3Kγ/δ inhibition) in orthotopic syngeneic GBM mouse models. Results: We identified three distinct functional TIME subtypes with unique vascular-immune landscapes in human and murine GBM: TIME-low (immune-low/deserted, leaky vasculature), TIME-med (intermediate immune-infiltration, angiogenic), and TIME-high (heavily infiltrated with immunosuppressive myeloid cells and dysfunctional T cells). Representative mouse models of TIME-GBMs responded in subtype specific ways to anti-angiogenic immunomodulating therapies. TIME-low GBMs enhanced T-cell activity but relapsed due to emerging myeloid immunosuppression, concomitant with mesenchymal transition. TIME-med displayed the most immune-activated, yet angiogenic phenotype, and showed overall good responses to various anti-angiogenic immunomodulating therapies. TIME-high GBMs were mostly non-responsive but improved when the myeloid-cell PI3Kγ was targeted. However, CD40 agonist treatment, expected to enhance APC function, unexpectedly worsened survival by promoting angiogenesis and heightening immunosuppression, leading to dysfunctional T cells and reduced NK cell recruitment, and subsequent enhanced tumor propagation. Conclusions: Our study reveals three GBM TIME subtypes with distinct vascular-immune landscapes that require tailored therapies. TIME-med tumors are predicted to respond best to immunotherapies, TIME-low tumors show transient effects with anti-angiogenic immunomodulating therapies, while TIME-high tumors, due to their profound immunosuppression, can even have worse outcomes. Key points: Three TIME subtypes were identified in GBM with distinct vascular-immune landscapes TIME subtypes show divergent immunotherapy responses TIME classification supports personalized treatment strategy for GBM immunotherapy Importance of the Study: This study advances glioblastoma immunotherapy by providing the first comprehensive single-cell characterization of TIME subtypes, moving beyond bulk RNA-sequencing to reveal detailed functional states of immune cells. We establish clinically relevant murine models that recapitulate human TIME subtypes, enabling preclinical testing of TIME-targeted therapies. Our findings identify TIME-low GBM as immune deserted and TIME-med tumors as the most immunotherapy-responsive subtype that should be prioritized for clinical selection. We found that high immune infiltration correlates with non-responsiveness and even unexpected detrimental effects with CD40 agonist treatment in TIME-high tumors—critical information given ongoing clinical trials. Identifying distinct immunosuppressive mechanisms across TIME subtypes and differential treatment responses provides a framework for personalized immunotherapy selection. The immediate translational impact of this work highlights the importance of TIME classification for treatment stratification and the urgent need to consider TIME status in clinical trial design, potentially explaining variable patient responses in previous GBM immunotherapy trials.